Abstract
BackgroundImmune checkpoint blockade (ICB) has achieved unprecedented success in treating multiple cancer types. However, clinical benefit remains modest for most patients with solid malignancies due to primary or acquired resistance....
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have